logo
Vipul Organics receives first commercial order for newly developed automotive organic intermediate

Vipul Organics receives first commercial order for newly developed automotive organic intermediate

Business Upturn17-06-2025

By Aditya Bhagchandani Published on June 17, 2025, 10:49 IST
Vipul Organics Limited has secured its first commercial order for a newly developed organic intermediate intended for final use in the automobile industry. This marks the company's strategic entry into a new product category and a significant industry segment beyond its traditional focus on dyes and pigments.
According to the company's announcement on June 17, 2025, the breakthrough comes after an 18-month approval process that followed an initial trial shipment. The new product, developed by Vipul Organics' in-house R&D team, is a specialty organic intermediate used in the manufacturing of key automotive components such as shock absorbers and bumper extensions.
Vipul P. Shah, Managing Director of Vipul Organics, commented, 'Receiving approval for the final product in the automobile industry underscores our capability to innovate and deliver to world-class standards. This development not only adds a high-value product to our portfolio but also marks our entry into a completely new industry segment.'
The compound significantly enhances durability, impact resistance, and wear tolerance of auto parts. Vipul Organics expects increasing demand for this compound, opening up a robust revenue stream in the automotive sector.
With over five decades in the chemical industry and a global presence across 45 countries, Vipul Organics closed FY25 with revenues of Rs 163 crore. The company continues to invest in R&D to expand its footprint in high-performance chemical applications.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Adani Power shares rise nearly 4% today; Gautam Adani outlines $15-20 billion annual investment plan
Adani Power shares rise nearly 4% today; Gautam Adani outlines $15-20 billion annual investment plan

Business Upturn

timean hour ago

  • Business Upturn

Adani Power shares rise nearly 4% today; Gautam Adani outlines $15-20 billion annual investment plan

By Aditya Bhagchandani Published on June 27, 2025, 10:05 IST Shares of Adani Power surged nearly 4% during Friday's session. This follows Chairman Gautam Adani's announcement of an aggressive investment roadmap for the group. The stock jumped 3.47% to trade at Rs 598.20 as of 10:02 AM, up Rs 20.05 from the previous close of Rs 578.15. Speaking at the group's annual general meeting, Gautam Adani stated that the Adani Group plans to invest $15–20 billion annually across its businesses over the next five years. The group is targeting 100 gigawatt of electricity generation capacity by 2030, with significant investments flowing into renewable energy, data centers, ports, airports, and urban infrastructure projects like the Dharavi redevelopment. Despite facing US regulatory scrutiny earlier this year, Adani emphasized that no one from the group has been charged under the US Foreign Corrupt Practices Act. He highlighted the group's strong balance sheet and operational resilience, mentioning consolidated revenues of Rs 2,71,664 crore and an EBITDA of Rs 89,806 crore for the last fiscal year. During Friday's trade, Adani Power touched an intraday high of Rs 603.30 and a low of Rs 574.20. The company's current market capitalization stands at Rs 2.30 lakh crore, with a P/E ratio of 17.81. Average daily trading volume is around 4.91 million shares. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Akzo Nobel India shares rise nearly 4% today after JSW Paints acquisition deal
Akzo Nobel India shares rise nearly 4% today after JSW Paints acquisition deal

Business Upturn

timean hour ago

  • Business Upturn

Akzo Nobel India shares rise nearly 4% today after JSW Paints acquisition deal

Shares of Akzo Nobel India jumped nearly 4% to ₹3,293.90 on the NSE during Thursday's session after JSW Paints officially confirmed the acquisition of Akzo Nobel India's promoter stake. The company disclosed that its promoters, Imperial Chemical Industries Limited and Akzo Nobel Coatings International B.V., have executed a definitive Share Purchase Agreement (SPA) with JSW Paints. The transaction involves JSW Paints acquiring up to the entire 74.76% promoter stake in Akzo Nobel India at ₹2,762.05 per share, representing a 16% discount to Thursday's closing price. The deal, valued at nearly ₹9,400 crore, marks a major consolidation in the Indian paints industry. Following the acquisition, JSW Paints will make an open offer for an additional stake as required under SEBI regulations. Subject to regulatory approvals, JSW is set to become the new promoter of Akzo Nobel India, with the sellers being reclassified to public shareholders. This strategic move by JSW Paints aims to strengthen its position in India's decorative and industrial paints market. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

Torrent Pharmaceuticals shares surge nearly 5% today as JPMorgan upgrades stock with Rs 3,800 target
Torrent Pharmaceuticals shares surge nearly 5% today as JPMorgan upgrades stock with Rs 3,800 target

Business Upturn

timean hour ago

  • Business Upturn

Torrent Pharmaceuticals shares surge nearly 5% today as JPMorgan upgrades stock with Rs 3,800 target

Shares of Torrent Pharmaceuticals jumped nearly 5% during Friday's session after global brokerage firm JPMorgan upgraded the stock to 'Overweight' and raised its target price to ₹3,800 from ₹3,650 earlier. The new target implies an upside potential of 18% from Thursday's closing price. JPMorgan cited strong growth momentum in India as a key driver for the upgrade, adding that the trend is expected to continue. The brokerage also highlighted improved visibility in Torrent Pharma's Brazil business, supported by robust underlying performance and a favorable base effect following currency headwinds. JPMorgan further noted Torrent's positioning to benefit from the emerging GLP-1 opportunity in India, leveraging its leadership in cardiometabolic care. According to the brokerage, this could add 100–200 basis points to Torrent's annual growth rate over time. The firm also mentioned that Torrent's Brazil business could see GLP-1 benefits in the future, though the impact may be delayed, with generic launches expected around mid-2026. Torrent's strong cash flow generation and its target to become debt-free by FY27 were also highlighted as positives. The stock is currently trading at 25x and 22x estimated earnings for FY26 and FY27, respectively. Out of the 33 analysts covering Torrent Pharmaceuticals, 21 have a 'Buy' rating, seven rate it 'Hold,' and five recommend 'Sell.' Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store